Dolby Family Ventures

About The Fund

Dolby Family Ventures (DFV) is an early-stage venture capital firm founded in 2014, headquartered in the USA, precisely in San Francisco, California. They are known for their deep-rooted commitment to investing in visionary entrepreneurs who are tackling complex science and engineering challenges. With a strong focus on advancing technology and innovation, DFV invests across a diverse portfolio that includes software, biotech, IoT & wearables, health tech, web security & privacy, cloud services & infrastructure, medical devices, healthcare & wellness, consumer, and pharmaceutical sectors. Their investment size ranges from a minimum of $300,000 to a maximum of $3,000,000, with a preferred investment 'sweet spot' of around $1,500,000. They are not just limited to equity investments; their expertise also covers Fund of Funds. The firm takes pride in its specialization in early, seed, and Series A funding stages, advocating for expansion within these realms. Their assets under management are reported to be $10,000,000. DFV values a strong ethical foundation, technical sagacity, and is committed to long-term collaborations, promoting revolutionary ideas that include groundbreaking research in neurosciences, life sciences platforms, as well as innovative ventures in sectors such as climate tech and digital deep tech. Portfolio companies such as Motif Neurotech, Montara Therapeutics, and Ursa Major Technologies exemplify their investment ethos, which is geared towards creating solutions with positive societal impact and tackling diseases such as Alzheimer’s. DFV is keen on supporting ventures that not only demonstrate potential for market disruption but also have a significant bearing on improving patient care and quality of life. Furthermore, DFV endorses a 'polymedicine' approach to treat complex diseases, reflecting a strategy that addresses diseases with multi-faceted therapeutic interventions. One key aspect of DFV's philosophy is their polymedicine strategy, which aims to simultaneously target multiple pathways to treat complex diseases more effectively. They actively invest in companies developing diagnostics and therapeutics, particularly for Alzheimer’s Disease, banking on broad collaboration for conquering such ailments. Despite their name, DFV is an independent entity and operates separately from Dolby Laboratories. They are recognized for their participatory role in venture creation, providing strategic insights, fostering networking among scientific experts, and acting as a bridge that connects founders to investors versed in neurological sciences and CNS-related fields. With a penchant for operational excellence and a significant network, DFV stands as more than an investor, but rather a partner and mentor for up-and-coming companies striving for scientific innovation.